An experimental lung-cancer drug could replace Keytruda one day. But investors aren’t wowed.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.